Pseudoxanthoma Elasticum: An Interesting Model to Evaluate Chronic Kidney Disease-Like Vascular Damage without Renal Disease

Luis D’Marco\textsuperscript{a} Marcos Lima-Martínez\textsuperscript{b} Cristina Karohl\textsuperscript{c} Maricarmen Chacín\textsuperscript{d} Valmore Bermúdez\textsuperscript{d}

\textsuperscript{a}Nephrology Department, Hospital Clinico Universitario, INCLIVA, Valencia, Spain; \textsuperscript{b}Department of Physiological Sciences, Universidad de Oriente, Bolívar, Venezuela; \textsuperscript{c}Universidade Federal do Rio Grande do Sul, Faculdade de Medicina, Porto Alegre, Brazil; \textsuperscript{d}Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia

\textbf{Abstract}

\textbf{Background:} Pseudoxanthoma elasticum (PXE; OMIM 264800) is an inherited multisystem disorder associated with accumulation of mineralized and fragmented elastic fibers in the skin, vascular walls, and brush membrane in the eye. Carriers exhibit characteristic lesions in the cardiovascular system, and peripheral and coronary arterial disease as well as mitral valvulopathy often present as a cardiovascular feature of this disease. PXE and chronic kidney disease (CKD) share some common patterns in the vascular damage and in therapeutic approaches as well. \textbf{Summary:} To date, treating PXE has focused more on careful follow-up examinations with retinal specialists and cardiologist, avoiding long-term anticoagulation. Like CKD, maintaining a low-calcium diet, increasing dietary magnesium, and administering phosphate binders such as aluminum hydroxide or sevelamer may yield a modest benefit. Recently, 4-phenylbutyrate acid (4-PBA) has demonstrated a maturation of ABCC6 mutant effects into the plasma membrane. Moreover, in a humanized mouse model of PXE, 4-PBA administration restored the physiological function of ABCC6 mutants, resulting in enhanced calcification inhibition and thus a promising strategy for allele-specific therapy of ABCC6-associated calcification disorders. \textbf{Key Message:} Vascular compromise in PXE patients share some components similar to CKD.

\textbf{Introduction}

Vascular calcification (VC) is an independent risk factor for cardiovascular disease. There are various degrees of vascular damage among patients with chronic kidney disease (CKD). Both traditional risk factors for atherosclerosis and factors more closely associated with progressive loss of kidney function contribute to increase the incidence of cardiovascular complications seen in these patients. Thus, 2 primary forms of arterial pathology develop in patients with CKD: atherosclerosis, with the accumulation of inflammatory cells, lipids, fibrous tissue, and calcium in the subintimal space, and arteriosclerosis [1]. The latter is characterized by a collection of hydroxyapatite deposits and amorphous calcium crystals in the vessel’s \textit{tunica media} and is believed to be more closely...
associated with alterations in mineral metabolism than with traditional atherosclerosis risk factors [2]. The result is the development of what appears to be premature arterial aging with loss of elastic properties, increases stiffness, and increased overall fragility of the arterial system.

_Pseudoxanthoma elasticum_ (PXE; OMIM 264800) is a rare genetic disorder caused by mutations in the ABCC6 gene which may function as a transporter and is mainly expressed in the kidneys and liver and characterized by elastorrhexia – a progressive calcification and fragmentation of elastic fibers in the skin (yellowish papules or plaques with “plucked chicken appearance”), retina (angiod streaks, peau d’orange, and choroidal neovascularization), and vessels (mainly by arterial calcification). In this sense, PXE is a considerable health threat due to severe visual impairment and blindness, peripheral arterial disease, ischemic stroke, mitral valve prolapse, and coronary artery disease resulting in _angina pectoris_ and subsequent myocardial infarction [3, 4].

PXE has been found in people all over the world irrespective of their ethnic background, but a higher prevalence has been detected in some populations like “Afrikaners” from South Africa and some isolated families in the Netherlands [5, 6]. Although PXE is a disease with high phenotypic variability and more than 300 mutations documented, the 4 most frequent mutations and variations in ABCC6 associated with PXE are R1141X, exon 23–29 deletion, R1164X, and Q378X, respectively [7]. R1141X is in exon 24 and represents about 30% of all PXE mutations. Allel-mediated deletions of exons 23–29 (del 23–29) is the second most common alteration and has been found in at least 20% of the cases. Other recurrent forms of mutations are: nonsense mutations (a codon is changed to a stop codon) Q378X in exon 9, R518X in exon 12, R1164X in exon 24, and a clustering of nonsense mutations in exons 24 and 28, which are present in the nucleotide-binding domain that are critical for ABCC6 function. Analysis of missense mutations indicated that frequencies of the mutations residing in the domain-domain interfaces are 3.5- to 4.1-fold higher than those of the entire protein [8]. The inheritance pattern reported in most families has been autosomal recessive, but PXE with autosomal dominant inheritance has also been reported [9]. This condition affects approximately 1 in 160,000 people with a female: male ratio of 2:1. The mean onset age of this disease is around 13 years, with a peak number of new cases between 10 and 15 years.

Typically, PXE appears with a formation of yellow papules containing abnormally calcified elastic fibers. Cutaneous lesions often appear in the neck, axilla, cubital fossa, inguinal region, and periumbilical area. Angiod streaks are typically seen in the fundus due to breaks in Bruch’s membrane [10]. Finally, clinical delineation of PXE may be confusing because limited manifestations can be detected in some heterozygous carriers, and because cutaneous findings mimicking PXE, or cardiovascular manifestations, can be found in the general population, although at an older age [11]. A recent review questioning autosomal dominant PXE concluded that this mode of inheritance might exist, but it would then be marginal [12].

Similar to CKD, patients affected with PXE have low levels of inorganic pyrophosphate (PPi), a strong inhibitor of ectopic mineralization [13] leading to a typical pattern of progressive calcification of elastic fibers in the skin, eyes, and vasculature [14]. Thus, PXE represents a model disease for arteriosclerosis as it is thought to have an isolated arteriosclerotic type of arterial wall disease with relatively little interference of atherosclerotic arterial wall disease [15].

**PXE and Renal Disease**

The renal involvement of PXE has been reported. Several factors are known to promote soft tissue and accelerated arterial calcification in CKD, including systemic inflammation, altered calcium and phosphate homeostasis, and deficiency in endogenous calcification inhibitors. Lau et al. [16] described for the first time that CKD results in acquired ABCC6 transporter deficiency and may contribute to CKD-associated vascular and soft tissue calcification. On the contrary, although calciphylaxis often occurs in patients with end stage renal disease and secondary hyperparathyroidism, nonuremic calciphylaxis has been described in PXE-affected patients without several forms of CKD [17]. To date, which specific area of the kidney is affected by PXE has been scarcely reported. To our knowledge, in patients with PXE, kidney disease mainly presents as nephrocalcinosis, glomerulonephritis, renovascular hypertension, and nephrolithiasis [18–20]. Histologically, small- to medium-sized renal arteries show elastic fiber fragmentation and mineralization [21]. Interestingly, despite extensive calcification of the renal vasculature reported in some cases, severe forms of CKD have not been described as a consequence of PXE alone.

The bone mineralization process has been investigated in PXE patients. For instance, in a study conducted by Martin et al. [22], patients with PXE were not markedly prone to excessive bone demineralization and risk of
fracture, and, as a consequence, the prevalence of osteoporosis remains as expected for the general population. Furthermore, the relationships between lower-limb arterial calcification, but not coronary artery calcification, and bone mineral density with age are similar to those observed in the general population. Therefore, despite its pivotal role in ectopic calcification, ABCC6 deficiency does not interfere with the bone-vascular axis. The lack of PXE-related disturbances between bone mineral density and arterial calcification also supports vitamin D supplementation in PXE patients with vitamin D deficiency. Of note, patients with moderate or severe CKD always express some degrees of bone demineralization, and the risk of fracture increases dramatically.

**Differences in Vascular Patterns**

Although vascular diseases in CKD and PXE share some common patterns, there are specific characteristics to consider (Table 1). An increase in the stiffness of the arterial wall is generally associated with aging and acquired metabolic diseases, such as diabetes and CKD or Monckeberg’s atherosclerotic disease [14, 23, 24]. Although the impact of vascular damage on the arterial bed in PXE remains unclear, the impairment in the elastic fiber-rich arterial walls are also involved in the pathology, resulting in precocious and slowly evolving segmental arterial narrowing [25]. Moreover, the internal elastic laminae of small and middle-sized arteries are mainly involved. Thus, the slow course of vessel narrowing is associated with the development of arterial collaterality. Consequently, severe vascular symptoms are infrequent in PXE. Kornet et al. [26] reported that a thicker and more elastic carotid artery was associated with elastin fragmentation and proteoglycan accumulation in PXE patients. Additionally, investigations have shown a tendency to increase the arterial stiffness, and others reduced stiffness or increased wall compressibility [27]. On the contrary, other reports suggested that arterial calcification in PXE is not accompanied by increased stiffness of the arterial wall [28].
Nevertheless, how relevant could this be in the elderly population or those affected with CKD or diabetes? It is clear that medial-artery calcification contributes to arterial stiffening, which results in hypertension and heart failure, but also pulse pressure-related damage in susceptible high-flow end organs like the kidneys [27]. Indeed, increased arterial stiffness is associated with worsening CKD and microvascular damage. To date, the relation of CKD progression in PXE patients has not been well investigated.

As we commented earlier, a complex network of calcification promoters and inhibitors is precisely tuned to inhibit calcification of the internal elastic laminae; thus, PPi is one of the most potent calcification inhibitors [2]. PPi binds to hydroxyapatite crystals inhibiting further growth of the calcifications [29]. As a result, disrupted PPi homeostasis is shown in monogenetic disorders as generalized arterial calcification in infancy and arterial calcification due to a deficiency in CD73, PXE, and CKD as well [29]. However, the main difference in the models of vascular damage between PEX and CKD lies in the bone-vascular axis involvement of the latter. Although, the pathophysiological mechanism underlying this phenomenon in CKD is still poorly understood, a large variety of conditions that can modulate the composition of the vascular microenvironment, such as bone turnover, inflammation, or oxidative stress, appears to be mainly responsible (Fig. 1) [2].

In the general population, arterial calcification is heterogeneously distributed across various vascular beds, predominating in the coronary arteries in men and the aorta in women [30]. Compared to other inherited calcifying diseases, the calcification process in PXE is generally considered to be slowly progressive, although extensive arterial calcification can develop in infancy [31]. In CKD, this process is accelerated when the glomerular filtration rate is <60 mL/min [32]. The calcification process within the arterial segments of the legs has reported as heterogeneous in PXE, with calcifications predominating in the femoral and subpopliteal arteries [28]. This heterogeneity is probably explained by the underlying pathophysiology, with calcification accumulating preferentially within the middle layers of the below-knee arteries in metabolic diseases and within the intima layer of the proximal arteries, such as the femoral artery, where atheroma predominates [28].

### Therapeutic Approaches

For both, CKD and PXE, the current treatment approach for decelerating CVD is based on the reduction in traditional cardiovascular risk factors through lifestyle changes (smoking cessation, weight loss, daily walking, and moderate physical exercise, etc.) and an appropriate diet with supplemented magnesium, phosphate binders, and pyrophosphate analogues (Table 2) [33]. Moreover, in CKD patients, the nephrologist keeps special attention to uremic-related risk factors like anemia, mineral bone disease, or inflammation, etc.

As in the pathophysiology, CKD and PXE have some therapeutic approaches in common. However, it has not been definitively demonstrated that medical treatment may halt the progression of vascular disease, but several therapies affecting bone and mineral metabolism may help attenuate disease progression [34]. In recent years, therapeutic methodologies to compensate the PPi deficit in animals and humans have been developed successfully [35]. In ABCC6–/– mice, the consumption of PPi-enriched food represents a possible intervention to mitigate calcification progression in PXE. In animal models, new data from Ziegler et al. [36] have shown that ABCC6-mutant cells had increased expression and activity of tissue-nonspecific alkaline phosphatase (TNAP), an enzyme that degrades PPi. Hence, a selective and orally bioavailable TNAP inhibitor prevented calcification in these cells in vitro and attenuated both the development and progression of calcification in vivo, without the harmful effects on bone associated with other proposed treatment strategies. This finding offers the rationale that TNAP inhibition would be useful in other disorders of ectopic calcification, including common conditions such as cardiac valve calcification and VC in CKD, in which decreased PPi has also been documented [34, 37, 38].

<table>
<thead>
<tr>
<th>Treatment/disease</th>
<th>CKD</th>
<th>PXE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle modification</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Pyrophosphate</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Magnesium</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>TNAP inhibitor</td>
<td>no</td>
<td>yes</td>
</tr>
<tr>
<td>Phosphate binders/SHPT</td>
<td>yes</td>
<td>yes/no</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Hyperaldosteronism</td>
<td>yes</td>
<td>no</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>yes</td>
<td>yes</td>
</tr>
</tbody>
</table>

TNAP, tissue-nonspecific alkaline phosphatase; SHPT, secondary hyperparathyroidism. ¹ Limited and conflicting data.
Improving the abnormalities of mineral metabolism like serum phosphate elevation and parathyroid hormone action has shown significant and independent associations between all-cause mortality and cardiovascular disease end-points in both, patients with normal kidney function and those with CKD. Management of hyperphosphatemia in CKD has involved dietary phosphate restriction, the use of phosphate binders, and dialysis in those with end stage renal disease [39]. Likewise, calcimimetics are used for the treatment of secondary hyperparathyroidism in patients with end stage renal disease. The oral calcimimetic cinacalcet has been associated with reduced VC progression [40]. At this stage, supplementation with K vitamin as a cofactor of matrix-Gla protein with potential slowing of calcification progression is under investigation [41]. In both human and animal studies, hyperaldosteronism is associated with vascular stiffness, damage, and accelerated atherosclerosis. Thus, research interest has increased in the role of hyperaldosteronism triggering osteoinductive changes in the vasculature [42].

Observational studies suggested that bisphosphonates might provide some protective effects on VC in CKD- and PXE-affected patients [43]. Bisphosphonates have anti-inflammatory properties and inhibit the expression of osteogenic proteins that could prove to be beneficial in slowing VC in CKD. The clinical efficiency of etidronate to counteract ectopic mineralization was recently determined in 74 patients with PXE in the TEMP (Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum) Trial [44]. After a 1-year follow-up, etidronate was found to inhibit arterial media layer calcification and reduce the incidence of ocular complications.

There is accumulating evidence that magnesium is able to suppress phosphate-induced VC in CKD [45]. Magnesium impairs the crystallization of calcium phosphate and, more specifically, the maturation of calciprotein particles. Is well known that phosphate overload causes kidney damage, and magnesium might counteract phosphate toxicity, as in the case of VC. Similarly, the effect of oral magnesium on the progression and severity of PXE has been tested. Although some improvement was noted in patients receiving magnesium supplementation, the results did not reach statistical significance.

Short-chain fatty acid 4-phenylbutyrate (4-PBA), used to treat urea cycle disorders and thalassemia as a nitrogen-scavenging molecule, has been recently employed to promote the maturation of ABCC6 mutants to the plasma membrane. This short-chain fatty acid also influences the transcription of chaperone proteins, and this physiological property has been used in familial intrahepatic choledasis type 2 that results in intracellular retention of an otherwise functional protein. In this regard, in a model of PXE, Pomozi et al. [35] investigated whether 4-PBA administration could block the calcification of ABCC6 mutants. This group employed a cardiac calcification phenotype of Abcc6–/– to quantify the effect of 4-PBA on human ABCC6 mutants expressed in hepatocytes, demonstrating that 4-PBA administration restored the physiological function of ABCC6 mutants, resulting in an enhanced calcification inhibition and identifying the 4-PBA molecule as a promising drug for ABCC6-associated calcification disorders.

Despite intensifying research and increasing awareness of these issues, the underlying pathophysiology of the vasculopathy of CKD and PXE remains mostly unknown. In conclusion, given the impact of these diseases, future investigations may seek additional supportive features to improve and avoid the risk of cardiovascular complications. Moreover, PXE per se represents an attractive model to evaluate the CKD-like vascular damage in non-renal affected models.

Disclosure Statement
All the authors declare to have no competing interests.

Funding Sources
There were no funding sources.

Author Contributions
All authors participated in the design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

References